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Abstract
BACKGROUND:  There is a clear need for simple and effective 
tests to identify individuals who are most likely to develop 
Alzheimer’s Disease (AD) both for the purposes of clinical trial 
recruitment but also for improved management of patients who 
may be experiencing early pre-clinical symptoms or who have 
clinical concerns. 
OBJECTIVES: To predict individuals at greatest risk of 
progression of cognitive impairment due to Alzheimer’s Disease 
in individuals from the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) using a polygenic risk scoring algorithm.  To 
compare the performance of a PRS algorithm in predicting 
cognitive decline against that of using the  pTau/Aß1-42 ratio 
CSF biomarker profile. 
DESIGN: A longitudinal analysis of data from the Alzheimer’s 
Disease Neuroimaging Initiative study conducted across over 50 
sites in the US and Canada.
SETTING: Multi-center genetics study.
PARTICPANTS: 515 subjects who upon entry to the study 
were diagnosed as cognitively normal or with mild cognitive 
impairment.
MEASUREMENTS: Use of genotyping and/or whole genome 
sequencing data to calculate polygenic risk scores and assess 
ability to predict subsequent cognitive decline as measured by 
CDR-SB and ADAS-Cog13 over 4 years.
RESULTS: The overall performance for predicting those 
individuals who would decline by at least 15 ADAS-Cog13 
points from a baseline mild cognitive impairment in 4 years 
was 72.8% (CI:67.9-77.7) AUC increasing to 79.1% (CI: 75.6-
82.6) when also including cognitively normal participants. 
Assessing mild cognitive impaired subjects only and using a 
threshold of greater than 0.6, the high genetic risk participant 
group declined, on average, by 1.4 points (CDR-SB) more than 
the low risk group over 4 years.  The performance of the PRS 
algorithm tested was similar to that of the pTau/Aß1-42 ratio 
CSF biomarker profile in predicting cognitive decline. 
CONCLUSION: Calculating polygenic risk scores offers a 
simple and effective way, using DNA extracted from a simple 
mouth swab, to select mild cognitively impaired patients who 
are most likely to decline cognitively over the next four years.
Key words: Polygenic risk, cognitive decline, Alzheimer’s disease.
Introduction
Alzheimer’s disease (AD) is the most common form of dementia with nearly 50 million people affected globally and an estimated economic 
impact of $818 billion (1).
As well as having a clear heritable component (2), AD 
is genetically complex. Neuropathologically, the disease 
is characterized by extracellular senile plaques containing 
β -amyloid (Aβ) and intracellular neurofibrillary tangles 
containing hyperphosphorylated tau protein. A relatively 
small number of dominant mutations in the amyloid 
precursor and presenilin genes are known to cause early 
onset Alzheimer’s disease. Over the past two decades, 
genome wide association studies (GWAS) have identified 
multiple loci and single nucleotide polymorphisms 
(SNPs) associated with the much more common, late-
onset or sporadic form of the disease (LOAD) (3-5). 
Apolipoprotein E (ApoE) is a major cholesterol carrier 
that supports lipid transport and injury repair in the 
brain. The ε4 allele of ApoE (ApoE4) has been found to 
be a primary genetic risk factor for AD, associated with 
increased risk for both early-onset AD and LOAD (6, 7). 
Although only 20-30% of humans are ApoE4 carriers, 
these individuals account for up to 60% of all Alzheimer’s 
disease cases. In addition, ApoE4 is associated with an 
increased risk of lower age of onset (8, 9), making this 
an important subset of the population at high risk of 
developing AD. 
Development of polygenic risk scoring (PRS) 
algorithms that can capture all the genetic contribution 
towards the risk of developing AD (10) is an attractive 
strategy to allow better clinical trials for AD prevention. 
PRS approaches have demonstrated accuracies of 
between 75 and 84% for predicting onset of AD when 
including APOE, sex and age in addition to PRS (11), In 
particular the PRS approach as developed by Escott-Price 
et al (12), is built as a sum of the weighted contributed of 
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10,000s of SNPs where the weights are the β-coefficients 
of each SNP association with the disease. In contrast to 
other PRS algorithms, where fewer SNPs have been used 
(for example just 31 SNPs (13)) this approach includes 
SNPs that are not considered as having genome wide 
significance in GWAS studies. However, inclusion of 
this vastly increased number of variants which alone 
carry sub-threshold significance provides an additive 
contribution to the overall performance that may be 
substantive and also reduce risk that performance is not 
lost when being applied across different cohorts.
Until now the analyses performed using this particular 
approach have been carried out to predict those 
individuals diagnosed with AD or MCI (14) versus those 
who are cognitively normal, though PRS algorithms have 
been used to look at a variety of AD pathology and risk 
by Altmann et al (15). Here we look to see how the PRS 
performs in predicting those individuals most likely to 
decline cognitively independent of whether they have 
cognitive impairment on entry or not. 
Currently, the most frequently used approach to 
enrich clinical trial recruitment with participants who 
have increased likelihood of progressive cognitive and 
functional decline has been to focus on identifying 
individuals who are positive for amyloid biomarkers. In 
addition, measurement of tau in CSF often with amyloid 
levels, is increasing in use. We therefore also compare the 
ability to predict decline using PRS against that of using 
CSF tau and amyloid measurements.
 
Methods
Data used in the preparation of this article were 
obtained from the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) database (adni.loni.usc.edu). The ADNI 
was launched in 2003 as a public-private partnership, led 
by Principal Investigator Michael W. Weiner, MD. The 
primary goal of ADNI has been to test whether serial 
magnetic resonance imaging (MRI), positron emission 
tomography (PET), other biological markers, and clinical 
and neuropsychological assessment can be combined to 
measure the progression of mild cognitive impairment 
(MCI) and early Alzheimer’s disease (AD).
Sample Description
ADNI is an on-going longitudinal study that has been 
established to develop methods for early detection of 
AD and subsequent monitoring of disease trajectory 
using clinical, imaging and genetic data (16). Data for 
this analysis was collected from 515 participants, who 
entered the study with a diagnosis of Mild Cognitive 
Impairment or considered cognitively normal. In 
addition, 47 individuals diagnosed with AD were used 
to check the algorithm was performing as expected to 
differentiate AD cases from cognitively normal controls. 
All participants in addition to having suitable genetic 
data available had at least 4 years’ worth of follow up 
cognitive testing and imaging scans. Upon entry into the 
study 199 individuals were cognitively normal and 316 
diagnosed as MCI. The average age of the total group 
was 73.2 years, with the CN group being on average 
approximately 3 years older than those diagnosed with 
MCI (75.1y and 72.0 y respectively). ADAS-Cog13 scores 
for cognitively normal and MCI groups upon entry were 
9.0 and 14.9 respectively and at the 4 year assessment 
the average scores obtained were 9.6 and 19.8, clearly 
showing that on average the MCI group continued to 
decline compared with little change in the average score 
of the CN group.  CSF biomarker data were not available 
for all participants, so analyses performed to compare 
PRS with biomarker (tau and amyloid) as a predictor 
for subsequent cognitive decline were carried out on 
290 MCI subjects. Table 1a shows the classification of 
the ADNI dataset at baseline and changes to cognitive 
performance as measured by ADAS-Cog13 after 4 years. 
Similarly, Table 1b describes the sub-group that also had 
CSF biomarker data available.
Genotyping Procedures and Quality Control
The ADNI samples were genotyped using with Whole 
Genome Sequencing and/or the Illumina Omni 2.5M 
BeadChip array. Quality control checks were performed 
using PLINK software (www.cog-genomics.org/
plink/2.0/) (17). Checks included exclusion of SNPs with 
missingness greater than 0.02, minor allele frequency 
of less than 0.01 and SNPs with Hardy-Weinberg 
equilibrium p-value less than 1 x 10-6 were also excluded. 
After such checks 8,990,292 SNPs were left for analysis 
of which approximately 114,000 were used as part of the 
polygenic risk scoring algorithm.
Calculation of Polygenic Risk Scores
A specifically built, proprietary software called 
SNPfitR was used for all subsequent PRS calculations. 
The  PRS calculations are based on a pre-determined 
logistic regression model based on the modelling of the 
association between the incidences of variants within  a 
large panel of SNPs  with a known links to AD to the 
presence of the disease in a substantial cohort of subjects 
(Escott-Price et al12). Subject age, gender and presence 
of both APOE4 and APOE2 proteins are included as 
covariates.  The software calculates the normalised sum 
of the individual scores weighted by their effect sizes for 
each SNP, adds the values for the covariates and derives 
the predicted risk from the model equation. 
Effect sizes were determined from the IGAP study. The 
score contribution from SNPs with missing values were 
imputed based on the population frequency of the effect 
allele for that SNP.
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Statistical Analysis
The polygenic risk scores generated were exported for 
the analysis presented.
The statistical analysis software package JMP 14.1.0 
was used to carry out all data manipulation and analysis. 
The ROC analysis and AUC calculations were performed 
using the add in ‘Model Classification Explorer’. Values 
were cross checked with the AUC calculations carried out 
in the software.
Results
Association of AD PRS with onset of 
Alzheimer’s Disease
As a check that the algorithm was performing as 
expected polygenic risks scores were also generated for 
47 Alzheimer Disease cases and compared with those 
generated for the 199 cognitively normal individuals. 
The accuracy of prediction of clinical AD cases (n = 47) 
versus cognitively normal control (n = 199) was 80% 
AUC. Furthermore, as shown in Figure 1, PRS score 
is clearly associated with tau levels and, as expected, 
diagnostic classification. In this analysis, data were 
plotted in this heat density format to illustrate a clear 
relationship between the pTau/Aß1-42 ratio (Hansson et 
al18) and the stage of disease.  It can be seen that those 
subjects classified at AD, late-MCI (LMCI) or early-MCI 
(EMCI), predominantly sit in the group with a PRS of 0.6 
or above, whereas cognitively normal (CN) individuals 
tend to be in the 0.6 or lower range of the PRS scores. 
Importantly, as shown in Figure 2, there is a substantial 
overlap between different APOE genotype sub-groups. 
As expected, ApoE4 carriers fall within the higher end 
(0.6 and above) end of the PRS range and ApoE2 carriers 
at the lower end.  However, ApoE3/3 homozygotes, 
representing some 60% of the Caucasian population, 
span the high and low ends of the PRS spectrum, thereby 
demonstrating the additional genetic risk information 
provided by the risk algorithm over APOE alone.
Association of AD PRS with cognitive decline 
from an MCI baseline
Rather than using specific clinical diagnosis to 
categorise cases as previously used, predicting the 
cognitive decline likely due to AD from either an MCI 
or cognitively normal baseline was performed. Table 
2 shows the predictive accuracy of identifying those 
individuals who are most likely to decline as measured 
by ADAS-Cog13 testing from an MCI or CN baseline, 
irrespective of cognitive status at baseline. The analyses 
were performed defining significant progression 
as 5-point, 10-point or 15-point decline at their 4 year 
follow up assessment.  Though we report the accuracy 
for predicting decline from a cognitively normal state, 
the number of individuals that decline significantly 
within the time period is relatively low and thus results 
cannot be considered statistically significant. However, 
of the 316 individuals who entered the study with an 
MCI diagnosis, significant numbers had declined by at 
least 5 points (107), 10 points (61) and 15 points (39) on 
the ADAS-Cog13 scale to allow meaningful prediction 
accuracies to be measured. In addition to the full PRS 
algorithm (APOE + PRS + Age + Sex) being used to 
generate risk scores, prediction accuracies based on 
APOE status alone and total genetic risk (APOE + PRS) 
were calculated.  The best prediction accuracy is seen for 
testing cases that have declined by at least 10 points at 4 
years versus those that have remained cognitively stable 
(< 5-point decline) with an AUC of 74.8%, compared 
with 67.4% for APOE alone and 73.5% for APOE + PRS. 
A similar performance is seen when predicting those 
individuals with 15-point decline. In both analyses all 
those individuals had polygenic risk scores in the upper 
half of the distribution. When looking at smaller changes 
in cognitive performance over 4 years, addition of the 
Figure 1. Density plots showing relationship between 
full  PRS, pTau/Aβ(1-42) ratio and diagnostic 
classification (CN, EMCI, LMCI, AD)
Figure 2. Distribution of risks scores across the MCI 
population (n = 316) coloured by APOE genotype
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polygenic risk score term to APOE did not impart greater 
performance. In all cases addition of age and gender 
as co-variates did not add any additional predictive 
performance in this particular group presumably due to 
the particular age and sex distribution between the CN 
and MCI groups in this particular cohort. Given that the 
mean age of those that declined and those that remained 
relatively stable were similar the contribution provided 
by age to the overall risk score for both groups would, in 
turn, be broadly equivalent. 
To evaluate whether the full algorithm could predict 
cognitive decline as defined by predetermined thresholds 
and be compared with that predicted by CSF biomarker 
status (figure 3), the MCI population where both genetics, 
CSF and CDR-SB assessment data were available was 
studied (n=290). There was a significant difference in 
progression (as defined by CDR-SB) between patients 
whose risk score was greater than 0.6 (n=196) versus 
the group whose score was less 0.6 (n=94) as early as 
6 months after baseline assessment. 0.6 was chosen 
as a threshold based on an optimal balance between 
sensitivity and specificity (data not shown here)   High 
risk patients progressed, on average, by approximately 
1 point over 24 months and 2 points over 48 months 
compared with low risk patients who on average 
decline 0.2 and 0.4 points over the same timepoints. 
A similar evaluation was carried out to compare the 
predictive performance using CSF biomarker positivity 
as determined by a pTau/Aβ(1-42) ratio using the cut 
off of 0.02818 and CSF Aβ(1-42) with a threshold of 
880pg/mL18. Again, there was a significant difference 
in progression between biomarker positive and 
negative patients. pTau/Aβ(1-42) ratio positive patients 
progressed, on average, by 1.1 and 2.9 points over 24 and 
48 months respectively, whereas there was an average 
decline of 0.1 and 0.2 points for the negative group. 
Similarly using Aβ(1-42) CSF levels only, the amyloid 
positive group progress by 1 and 2.6 points at 24 and 
48 months respectively whilst the negative group only 
progressed by 0,3 points on average over 48 months. The 
performance of the PRS was broadly similar to that of 
either CSF biomarker measurement in identifying those 
subjects at highest and lowest risk of cognitive decline 
on the CDR-SB scale. Furthermore, a similar analysis 
was performed on APOE3 homozygote individuals 
(n=125) only (figure 3). Again, using a threshold of 0.6 
Table 1. Characteristics of participants used in the analyses 
1a Characteristics of Participants – Genetic Data only
Characteristics MCI at Baseline Cognitively Normal at Baseline Total Group
Number 316 199 515
Age mean (SD) 72.0 (7.4) 75.1 (5.5) 73.2 (6.9)
Male/Female 188/128 97/102 285/230
ADAS-Cog13 at baseline mean (SD) 14.9 (6.3) 9.0 (4.1) 12.6 (6.3)
ADAS-Cog13 at year 4 mean (SD) 19.8 (14.1) 9.6 (5.1) 15.8 (12.5)
Number declining >5 points at 4yr 107 26 133
Number declining >10 points at 4yr 61 4 65
Number declining > 15 point at 4yr 39 1 40
1b Characteristics of MCI Participants - Tau CSF, Genetic Data and CDR-SB assessment are available
Number 290
Age mean (SD) 72.3 (7.3)
Male/Female 179/111
CDR-SB at baseline mean (SD) 14.6 (6.3)
CDR-SB at year 4 mean (SD) 19.7 (14.4)
PRS positive (>0.6) 196
PRS negative (<0.6) 94
Clinical Status at 
Baseline






















MCI (N =316) 65.8(60.6-71.0) 66.7(61.5-71.9) 68.8(63.7-73.9) 67.4(62.2-72.6) 73.5(68.6-78.4) 74.8(70.0-79.6) 67.3(62.1-72.5) 73.4(68.5-78.3) 72.8(67.9-77.7)
CN (N=199) 66.1(59.5-72.7) 63.1(56.4-69.8) 65.2(58.6-71.8) 64.7(58.1-71.3) 89.9(85.7-94.1) 91.9(88.1-95.7) - - -
MCI & CN (n = 515) 67.5(63.5-71.5) 69.5(65.5-73.5) 71.3(67.4-75.2) 70.2(66.2-74.2) 79.8(76.3-83.3) 80.6(77.2-84.0) 71.5(67.6-75.4) 79.9(76.4-83.4) 79.1(75.6-82.6)
* PRS = all risk associated with the genetics other than that contribution from APOE
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to determine the high risk group (n =49), a difference 
a measured by a change of CDR-SB between the two 
groups was shown 12 months with a clear difference at 
36 months. The high risk group declined, on average by 
1.5 points at 36 months compared with the low risk group 
who only declined, on average, by 0.5 points.   
 
Discussion
This study was designed to demonstrate the 
potential utility of a specific PRS algorithm in 
identifying individuals at highest risk of clinically 
significant cognitively decline within a specific time 
period. Previously most studies reporting the use of 
PRS approaches have been used to differentiate two 
populations with clearly different clinical phenotypes 
(AD versus CN) and thus not necessarily demonstrating 
how this approach could be used prospectively. The 
results of these analyses show that using polygenic 
scoring algorithms which have been designed to 
understand the genetic risk of future onset of Alzheimer’s 
Disease, can be applied to enrich trial populations with 
individuals who are more likely to decline cognitively 
within a certain time period.
Though APOE genotype remains an important 
genetic risk factor within this cohort, it is clear there is an 
additional genetic component that should be considered 
in assessing genetic risk. This will subsequently allow 
further risk stratification within APOE genotypes such 
as identifying APOE3 homozygotes who are at relatively 
higher risk even compared with some APOE4 carriers. 
This has implications in the design of clinical trials where 
in many trial designs possession of at least one APOE4 
allele is used as an enrichment strategy in prevention 
trials. 
It is broadly accepted that CSF-tau/amyloid ratios are 
a reasonable predictor of future cognitive decline (18-
20) though definitive studies have yet to be performed, 
and testing for amyloid alone, via PET imaging or CSF 
remains the standard method to enrich trials with patient 
most likely to decline cognitively. This study shows 
that PRS predictions, are able to perform to a similar 
level in predicting further progression, as measured 
by CDR-SB, in patients who have an MCI diagnosis. 
Importantly this genetic risk assessment can be more 
easily accessed (cost and patient burden) through whole 
blood or mouth swab testing, rather than by performing 
an invasive lumbar puncture procedure and subsequent 
CSF testing; such invasive procedures are particularly 
challenging in elderly subjects who may be relatively 
cognitively robust (early MCI or prodromal).  The PRS 
algorithm therefore represents a promising method to 
facilitate broad screening of potential trial participants 
in order to identify those at highest risk for cognitive 
decline. Further confirmatory testing, via the use of more 
invasive and expensive CSF and/or PET imaging, could 
then be focussed on a significantly reduced number 
Figure 3. Time course of clinical progression in patients with MCI over 48 months. Average with standard errors by 
PRS group (orange >0.6; blue <0.6 at baseline) for all APOE genotypes and for APOE homozygotes only,  pTau/Aβ(1-
42) group (orange > 0.028; blue <0.028) and Aβ(1-42) (orange < 880pg/mL; blue >880pg/mL)
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of individuals for final patient recruitment decisions. 
Furthermore, a combination of PRS and tau levels 
(underlying genetic risk coupled with manifestation 
of that risk through pathology) may provide a more 
optimal model for likelihood of subsequent onset of AD 
in early symptomatic or pre-symptomatic individuals. 
Whilst there may be specific reasons why amyloid or tau 
biomarkers may be required for clinical trials focussing 
on treatments specifically targeting amyloid or tau, 
PRS may have advantages for therapies with different 
treatment targets independent of potential mechanisms.    
Further studies will be important to determine the 
added value of combing amyloid/tau and PRS markers 
and to fully determine the utility of PRS in predicting 
cognitive decline in cognitively normal individuals. 
It is recognised that this work has considered genetic 
risk together with age and gender in developing a 
model for predicting further development of cognitive 
symptoms and so does not consider other risk factors 
that are known to influence onset and development of 
disease. Combining both genetic and lifestyle risk factors 
for the purposes of identifying those individuals most at 
risk of Alzheimer’s Disease is likely to add further to the 
predictive accuracy.
Study Limitations
This study is not without limitations, with sample size 
being the primary shortcoming. This was particularly 
relevant in evaluating the APOE E3 homozygote only 
sub-group. Furthermore, studies with larger sample 
sizes across all diagnostic categories, including those 
declining from a cognitively normal baseline, is 
important to understand broader utility. As with most 
studies of this nature, observing similar performance in 
alternative cohorts is important and is critical towards the 
understanding and confirmation of polygenic risk score 
assessment for use in clinical trial recruitment and in 
clinical practice. 
 
*Data used in preparation of this article were obtained from the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the 
investigators within the ADNI contributed to the design and implementation of 
ADNI and/or provided data but did not participate in analysis or writing of this 
report. A complete listing of ADNI investigators can be found at: http://adni.loni.
usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
Acknowledgements: Data collection and sharing for this project was funded by 
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of 
Health Grant U01 AG024904) and DOD ADNI (Department of Defense award 
number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, 
the National Institute of Biomedical Imaging and Bioengineering, and through 
generous contributions from the following: AbbVie, Alzheimer’s Association; 
Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; 
Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan 
Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La 
Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; 
IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; 
Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; 
Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; 
Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; 
Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition 
Therapeutics. The Canadian Institutes of Health Research is providing funds to 
support ADNI clinical sites in Canada. Private sector contributions are facilitated 
by the Foundation for the National Institutes of Health (www.fnih.org). The 
grantee organization is the Northern California Institute for Research and 
Education, and the study is coordinated by the Alzheimer’s Therapeutic Research 
Institute at the University of Southern California. ADNI data are disseminated by 
the Laboratory for Neuro Imaging at the University of Southern California. We 
also acknowledge Prof. Julie Williams, Prof. Valentina Escott-Price, Dr Rebecca 
Sims and Dr Eftychia Bellou from the University of Cardiff for their advice on 
adaptation and implementation of of the polygenic risk algorithm.
 
Funding: Funding for this study was provided under an Innovate UK grant 
(Project No 5195).
Conflict of Interest: P. Daunt, A.Gibson, O.Oshota and R. Pither are all 
employees of Cytox Ltd. G. Davidson received payment from Cytox Ltd. for work 
done both within and outside the scope of this article.
Ethical Standards: The ADNI protocols were approved by all the Institutional 
Review Boards of the participating institutions. Only data from volunteers who 
had provided written informed consent were used to complete these analyses.
Open Access: This article is distributed under the terms of the Creative 
Commons Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/), which permits use, duplication, adaptation, distribution and 
reproduction in any medium or format, as long as you give appropriate credit 
to the original author(s) and the source, provide a link to the Creative Commons 
license and indicate if changes were made.
References
1. Prince M, Wimo A, Guerchet M et al. World Alzheimer Report 2015: the 
Global Impact of Dementia – An analysis of prevalence, incidence, cost and 
trends. Alzheimer’s Dis Int 2015; 84:425
2. Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for 
explaining Alzheimer’s disease. Arch Gen Psychiatry 2006; 63: 168-174
3. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 
individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat 
Genet 2013; 45: 1452-1458
4. Naj, AC, Jun G, Beecham, GW et al. Common variants at MS4A4/MS4A6E, 
CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. 
Nat Genet 2011; 43: 436-441
5. Seshadri, S, Fitzpatrick AL, Arfan Ikram M et al. Genome-wide analysis of 
genetic loci associated with Alzheimer disease. JAMA 2010; 303: 1832-1840
6. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene Dose of 
Apolipoprotein-E Type-4 Allele and the Risk of Alzheimers-Disease in Late-
Onset Families. Science1993;261:921–923.
7. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on 
the association between apolipoprotein E Genotype and Alzheimer Disease: a 
Meta-analysis. JAMA 1997;278:1349–1356.
8. Blacker D, Haines JL, Rodes L, et al. ApoE-4 and age at onset of Alzheimer’s 
disease: the NIMH genetics initiative. Neurology 1997;48;139-147
9. Bonham LW, Geier EG, Fan CC, et al. Age-dependent effects of APOE ε4 in 
preclinical Alzheimer’s disease. Ann Clin Transl Neurol 2016;3;668-677
10. Stocker H, Möllers T, Perna L, et al, The genetic risk of Alzheimer’s disease 
beyond APOE ε4: systematic review of Alzheimer’s genetic risk scores. Transl 
Psych 2018;8;166-174
11. Escott-Price V, Myers A, Huentelman AJ, et al, Polygenic risk score analysis of 
pathologically confirmed Alzheimer’s disease. Ann Neurol 2017;82;311-314
12. Escott-Price V, Sims R, Williams J et al, Common polygenic variation enhances 
risk prediction for Alzheimer’s disease. Brain 2015;138;3673-3684
13. Desikan RS, Fan CC, Wang Y et al, Genetic assessment of age-associated 
Alzheimer disease risk: development and validation of polygenic hazard 
score. PLoS Med 2017 e1002258
14. Escott-Price V, Leonenko G, Sims R et al, Polygenic risk and hazard scores for 
Alzheimer’s disease prediction. Ann Clin Transl Neurol 2019;6;456-465
15. Altmann A, Schott JM, Scelsi et al, A comprehensive analysis of methods 
for assessing polygenic burden on Alzheimer’s disease pathology and risk 
beyond APOE. Brain Commun 2020;2;fcz047
16. Peterson R, Aisen PS, Beckett LA et al, Alzheimer’s Disease Neuroimaging 
Initiative (ADNI): clinical characterization. Neurology 2010;74;201-209
17. Chang CC, Chow CC, Tellier LCAM et al, Second-generation PLINK: rising to 
the challenge of larger and richer datasets. GigaScience 2015;4;s13742
18. Hansson O, Seibyl J, Stomrud et al, CSF biomarkers of Alzheimer’s disease 
concord with amyloid-β PET and predict clinical progression: A study of 
fully automated immunoassays in BioFINDER and ADNI cohorts. Alzhemers 
Dement 2018;14;1470-1481.
19. Ritchie C, Smailagic N, Noel-Storr et al, CSF tau and CSF tau/ABeta ratio 
for the diagnosis of Alzheimer’s disease dementia and other dementias in 
people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 
2017;3;CD10803.
20. Wolfsgruber S, Polcher A, Koppara A et al. Cerebrospinal fluid biomarkers 
and clinical progression in patients with subjective cognitive decline and mild 
cognitive impairment. Alzheimers Dis 2017;58;939-950.
